Effects of Celecoxib After Percutaneous Coronary Intervention

Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00292721

Enrollment

260

Registered

2006-02-16

Start date

2004-08-31

Completion date

2008-10-31

Last updated

2011-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Arteriosclerosis

Brief summary

Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

Interventions

DRUGCelecoxib

celecoxib: loading and maintenance for 6 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography

Exclusion criteria

* Acute ST elevation MI * Left main disease * Contraindications to aspirin, clopidogrel or celecoxib * Severe congestive heart failure * Expected survival \< 2 years * Hepatic dysfunction * Currently taking NSAIDs or any COX-2 inhibitor * Renal dysfunction * Use of warfarin

Design outcomes

Primary

Measure	Time frame
Late luminal loss at 6 months	6 months

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026